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Question
To test blood interferon signature as a screening tool for
type I interferonopathies in children with early-onset
SLE and vasculopathy.
Methods
We collected blood samples from a cohort of pediatric
rheumatologic patients and scored them according to a
qPCR based IFN gene signature assay. Expression of 6
type I IFN-related genes (IFI27, IFI44L, IFIT1, ISG15,
RSAD2, SIGLEC1) was quantified by standard RTPCR
techniques. An IFN score was calculated for each
patient using the median fold change of gene expression
related to a healthy control. Patients were selected based
on the presence of the following features: i) atypical or
incomplete SLE-like symptoms occurring in infancy or
in preprepubertal age; ii) vasculopathy (skin ulcers, chil-
blains, strokes) iii) panniculitis with or without lypody-
strophy iv) interstitial lung disease in the context of
systemic inflammation.
Results
We screened 24 patients from the rheumatology unit of
the Gaslini Children’s Hospital, Genova (Italy). 14 out of
24 patients had a positive signature with an IFN score
ranging from 3.5 to 23,7. Based on the clinical presenta-
tion and the result of the IFN score we further analyzed
two patients for mutations affecting TMEM173 gene: in
one patient we identified the previously reported
V155M variant and in the second patient we identified a
new variant whose pathogenic significance is currently
under study. Molecular screening for genes associated to
type I Interferonopathies and whole exome sequencing
is ongoing for selected patients.
Conclusions
Several studies have shown how mutation in genes
involved in type I interferon (IFN) pathway can be
responsible of severe inflammatory syndromes such as
Aicardi-Goutières syndrome (AGS) and spondyloench-
ondrodysplasia with immune disregulation (SPENCD).
STING associated vasculopathy with onset in infancy
(SAVI) and a familial inflammatory syndrome with sys-
temic lupus erythematosus (SLE)-like manifestations are
among the last clinical phenotypes that have been linked
to an increase of type I IFN - in both cases as a result of
TMEM173 gain of function dominant mutations. With
the present ongoing study we anticipate that testing
blood for an interferon signature is a valuable screening
tool for the identification of type I interferonopathies in
selected children with rheumatic diseases.
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